Fennec Pharmaceuticals (FENC) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Tectonic Therapeutic (TECX) over the past year, gaining 66.1% versus a gain of 8.1%. Over five years, FENC leads with a +35.8% price change compared with -57.7% for TECX. Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $405.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | TECX |
|---|---|---|
| Share price | $13.09 | $20.73 |
| Market cap | $462.14M | $405.26M |
| 1-day change | -2.68% | -1.47% |
| YTD return | +70.00% | -0.62% |
| 1-year return | +66.12% | +8.08% |
| 5-year return | +35.79% | -57.66% |
| P/E ratio (TTM) | 436.33 | — |
| Forward P/E | 12.47 | — |
| EPS (TTM) | $0.03 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.64M | — |
| Revenue growth (YoY) | -6.09% | — |
| Net income (latest FY) | $-9.74M | $-74.15M |
| Operating margin | -14.07% | — |
| Net margin | -21.82% | — |
| 52-week high | $13.85 | $39.53 |
| 52-week low | $5.65 | $16.77 |
| Distance from 52-week high | -5.49% | -47.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +34.45% | +242.50% |
| Average volume | 220.87K | 212.16K |
| Shares outstanding | 35.31M | 19.55M |
| Employees | 35 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed TECX by 58.0 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
FENC vs TECX FAQ
Which is bigger, Fennec Pharmaceuticals or Tectonic Therapeutic?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $405.26M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, FENC or TECX?
FENC returned +66.12% over the past 12 months, compared with +8.08% for TECX (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.